During the last session, Fresenius Medical Care AG ADR (NYSE:FMS)’s traded shares were 0.87 million, with the beta value of the company hitting 0.86. At the end of the trading day, the stock’s price was $26.81, reflecting an intraday loss of -0.48% or -$0.13. The 52-week high for the FMS share is $30.46, that puts it down -13.61 from that peak though still a striking 33.12% gain since the share price plummeted to a 52-week low of $17.93. The company’s market capitalization is $15.73B, and the average intraday trading volume over the past 10 days was 0.45 million shares, and the average trade volume was 464.95K shares over the past three months.
Fresenius Medical Care AG ADR (FMS) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 2.76. FMS has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.46.
Fresenius Medical Care AG ADR (NYSE:FMS) trade information
Fresenius Medical Care AG ADR (FMS) registered a -0.48% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.48% in intraday trading to $26.81, hitting a weekly high. The stock’s 5-day price performance is -7.36%, and it has moved by -10.18% in 30 days. Based on these gigs, the overall price performance for the year is 34.25%. The short interest in Fresenius Medical Care AG ADR (NYSE:FMS) is 1.71 million shares and it means that shorts have 2.82 day(s) to cover.
The consensus price target of analysts on Wall Street is $17.85, which implies a decrease of -50.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $11.7 and $24 respectively. As a result, FMS is trading at a premium of 10.48% off the target high and 56.36% off the low.
Fresenius Medical Care AG ADR (FMS) estimates and forecasts
In the rating firms’ projections, revenue will increase 1.54% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 5B as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 5.02B by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 4.77B and 4.76B respectively. In this case, analysts expect current quarter sales to grow by 4.97% and then jump by 5.37% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -14.87%. While earnings are projected to return 30.18% in 2025, the next five years will return 17.16% per annum.
FMS Dividends
Fresenius Medical Care AG ADR is due to release its next quarterly earnings on 2025-May-06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Fresenius Medical Care AG ADR is 0.79, with the dividend yield indicating at 2.94 percent, continuing the trend of increasing dividends in recent years. The average dividend yield of the company for the last 5 years is 1.3%.
The next largest institutional holding, with 5.17 million shares, is of FIDUCIARY MANAGEMENT INC /WI/’s that is approximately 1.762% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $98.69 million.
